Ob/Gyn Panel Illuminates Luma Trial Design Problem Areas For MediSpectra
This article was originally published in The Gray Sheet
Executive Summary
MediSpectra should design and perform a new study to address more closely the specific indication in the firm's PMA for the Luma cervical imager, according to FDA's Obstetrics & Gynecology Devices Panel
You may also be interested in...
MediSpectra’s Luma gains PMA approval
A cervical imager that works to identify pre-cancerous cells won PMA approval March 16 from FDA, overcoming last May's 9-2 vote against approving the device from the agency's Obstetrics & Gynecology Devices advisory panel based on concerns about the device's high false positive rate (1"The Gray Sheet" May 23, 2005, p. 11). MediSpectra says when used in conjunction with colposcopy, Luma - the first optical imaging device approved as an aid to clinicians examining women with abnormal Pap tests - identifies sites on the cervix that may contain pre-cancerous cells. FDA's approval was based on data from a study of 193 women that showed Luma detected additional cancer precursors missed by colposcopy...
MediSpectra’s Luma gains PMA approval
A cervical imager that works to identify pre-cancerous cells won PMA approval March 16 from FDA, overcoming last May's 9-2 vote against approving the device from the agency's Obstetrics & Gynecology Devices advisory panel based on concerns about the device's high false positive rate (1"The Gray Sheet" May 23, 2005, p. 11). MediSpectra says when used in conjunction with colposcopy, Luma - the first optical imaging device approved as an aid to clinicians examining women with abnormal Pap tests - identifies sites on the cervix that may contain pre-cancerous cells. FDA's approval was based on data from a study of 193 women that showed Luma detected additional cancer precursors missed by colposcopy...
Cervical Imaging Device Prompts FDA Panel Concern With False Positives
FDA's Obstetrics & Gynecology Devices Panel concluded May 17 that MediSpectra's pivotal studies failed to show a statistically significant benefit for the Luma cervical imager